Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)

Next Previous
Trial Profile

A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs THR 149 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors Oxurion

    • Most Recent Events

    • 18 Oct 2019 According to an Oxurion media release, data from this study were presented at major Retinal Conferences in Europe and the US including 19th Congress of European Society of Retina Specialists (EURETINA), Retina Society Annual Meeting and the American Academy of Ophthalmology Annual Meeting (AAO).
    • 09 Oct 2019 Results presented in an Oxurion media release.
    • 09 Oct 2019 According to an Oxurion media release, clinical update will be presented at upcoming Ophthalmology Innovation Summit (OIS) meeting which will be held on 10th October 2019, at the Hilton San Francisco Union Square.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top